Concepedia

Development of thioquinazolinones, allosteric Chk1 kinase inhibitors

Antonella Converso, Timothy J. Hartingh, R. M. Garbaccio, Edward S. Tasber, Keith Rickert, Mark E. Fraley, Youwei Yan, Constantine Kreatsoulas, Steve Stirdivant, Bob Drakas,

Bioorganic & Medicinal Chemistry Letters · 2008 · 74 citations · 11 references

DOIFull text

Open access

Concepts

References

11

G2 checkpoint abrogators as anticancer drugs

Takumi Kawabe · Molecular Cancer Therapeutics · 2004 · 383 citations · Full text

, , +17

Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells

Kalli Koniaras, Andrew Cuddihy, Helen Christopoulos et al. · Oncogene · 2001 · 180 citations

, , +14

Two structures of the catalytic domain of phosphorylase kinase: an active protein kinase complexed with substrate analogue and product

DJ Owen, AC Papageorigiou, LN Johnson · Structure · 1995 · 151 citations · Full text

, , +12

Selective Chk1 inhibitors differentially sensitize p53‐deficient cancer cells to cancer therapeutics

Zehan Chen, Zhan Xiao, Wen‐Zhen Gu et al. · International Journal of Cancer · 2006 · 129 citations · Full text

, , +17

Chk1 is Essential for Tumor Cell Viability Following Activation of the Replication Checkpoint

Song H. Cho, Christian D. Toouli, Gregory H. Fujii et al. · Cell Cycle · 2004 · 121 citations

, , +17